Improving Treatments - Improving Lives

Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. All clinical studies for Envarsus®, including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale of Envarsus®. Envarsus® has been granted Orphan Drug Status by the FDA.



FEATURED EVENT

Dec 16, 2014
Veloxis announces that it has filed an action against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.

PDF Veloxis Announces Action against the FDA
 200.9 KB   Add to Briefcase
PDF Veloxis offentliggør at have anlagt retssag mod FDA
 178.0 KB   Add to Briefcase
PDF Veloxis Complaint
 255.9 KB   Add to Briefcase

Nov 13, 2014
Presentation of the Interim Report for the 3rd Quarter 2014

Webcast Q3 2014 Audiocast
PDF Q3 2014 Interim Report
 760.2 KB   Add to Briefcase
PDF Q3 2014 Presentation
 379.0 KB   Add to Briefcase

 

 

  


Stock Information

QUICK LINKS